This study is testing a new medicine called vadadustat for people with anemia (low red blood cell count) caused by CKD (Chronic Kidney Disease) who go to a center for hemodialysis (a treatment that cleans the blood). The study will compare vadadustat, taken three times a week, to the usual medicine used, called an ESA (Erythropoiesis-Stimulating Agent). The study lasts about 33 weeks, which includes time to decide if you can join and check-ups after treatment.
Key Points:
- Length: The study will last around 33 weeks.
- Visits: You must visit the dialysis center at least three times a week.
- Risks: Some people may not be able to join if they can't take vadadustat or have certain health issues.